| # | Title | Journal | Year | Citations |
|---|
| 1 | A roadmap for graphene | Nature | 2012 | 8,011 |
| 2 | Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma | New England Journal of Medicine | 2009 | 7,606 |
| 3 | Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine | 2019 | 4,108 |
| 4 | The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis | Science | 2013 | 3,945 |
| 5 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
| 6 | Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus | New England Journal of Medicine | 2013 | 3,017 |
| 7 | Core outcome measures for chronic pain clinical trials: IMMPACT recommendations | Pain | 2005 | 2,915 |
| 8 | Drug repurposing: progress, challenges and recommendations | Nature Reviews Drug Discovery | 2019 | 2,689 |
| 9 | Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity | FEBS Journal | 2000 | 2,677 |
| 10 | Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | 2009 | 2,644 |
| 11 | Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer | New England Journal of Medicine | 2017 | 2,631 |
| 12 | Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations | Journal of Pain | 2008 | 2,564 |
| 13 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | New England Journal of Medicine | 2017 | 2,256 |
| 14 | Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry | Nature Protocols | 2011 | 2,236 |
| 15 | Pericytes regulate the blood–brain barrier | Nature | 2010 | 2,214 |
| 16 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Lancet, The | 2005 | 2,057 |
| 17 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | New England Journal of Medicine | 2018 | 1,854 |
| 18 | Core outcome domains for chronic pain clinical trials: IMMPACT recommendations | Pain | 2003 | 1,850 |
| 19 | AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 1,802 |
| 20 | What is meant by intention to treat analysis? Survey of published randomised controlled trials | BMJ: British Medical Journal | 1999 | 1,784 |
| 21 | Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme | Lancet, The | 2003 | 1,752 |
| 22 | AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer | Cancer Discovery | 2014 | 1,655 |
| 23 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Lancet, The | 2010 | 1,584 |
| 24 | Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | New England Journal of Medicine | 2019 | 1,521 |
| 25 | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes | New England Journal of Medicine | 2017 | 1,455 |
| 26 | Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 | Autophagy | 2021 | 1,430 |
| 27 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2017 | 1,376 |
| 28 | Guidelines for Treatment of Candidiasis | Clinical Infectious Diseases | 2004 | 1,371 |
| 29 | Rosuvastatin in Older Patients with Systolic Heart Failure | New England Journal of Medicine | 2007 | 1,330 |
| 30 | Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases | Lancet Infectious Diseases, The | 2013 | 1,328 |
| 31 | Olaparib for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine | 2020 | 1,327 |
| 32 | Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M | Nature Medicine | 2015 | 1,280 |
| 33 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial | Lancet, The | 2019 | 1,274 |
| 34 | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial | Lancet, The | 2008 | 1,248 |
| 35 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial | Lancet Oncology, The | 2014 | 1,237 |
| 36 | Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial) | American Journal of Cardiology | 2003 | 1,217 |
| 37 | Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? | Journal of Medicinal Chemistry | 2016 | 1,187 |
| 38 | Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes | Cell Metabolism | 2016 | 1,173 |
| 39 | Guidelines for the welfare and use of animals in cancer research | British Journal of Cancer | 2010 | 1,167 |
| 40 | A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) | Journal of Thoracic Oncology | 2014 | 1,131 |
| 41 | Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores | Journal of Cell Biology | 2003 | 1,117 |
| 42 | High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study | Lancet, The | 2001 | 1,093 |
| 43 | Targeting the DNA Damage Response in Cancer | Molecular Cell | 2015 | 1,093 |
| 44 | Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet, The | 2016 | 1,070 |
| 45 | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Journal of Thoracic Oncology | 2017 | 1,067 |
| 46 | Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Lancet, The | 2016 | 1,050 |
| 47 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Lancet Oncology, The | 2011 | 1,028 |
| 48 | An analysis of the attrition of drug candidates from four major pharmaceutical companies | Nature Reviews Drug Discovery | 2015 | 996 |
| 49 | Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism | Nature Reviews Drug Discovery | 2003 | 975 |
| 50 | Organic synthesis provides opportunities to transform drug discovery | Nature Chemistry | 2018 | 931 |
